Report date: Thursday, July 30, 2026 | Event: 2026Q2 Earnings Call
Corteva heads into its second-quarter print in a strong position, both operationally and stock-wise. Shares have run from roughly $68 in early January 2026 to nearly $91 as of July 29, a gain of about 34% year-to-date, putting the stock near 52-week highs right before the print — a setup that raises the bar for what the market will consider "good enough."
The fundamental backdrop looks favorable heading in. On the Q1 2026 call (early May), CEO Chuck Magro characterized the season constructively: "Planting in the Northern Hemisphere is proceeding well. The weather has cooperated for the most part, and we are well positioned with technology that is in high demand." He also flagged that "farmers remain cautious and value driven" and that crop-mix decisions are being made strategically around the strongest demand signals — a dynamic investors should watch for in the Q2 seed/crop-protection mix.
Corteva's first quarter came in well ahead of expectations, but investors should remember management's own caution that first-quarter results don't dictate the full year and that Q1/Q2 volumes routinely shift back and forth given planting-season timing. Key Q1 2026 metrics:
Management attributed part of the strength to a pull-forward effect: "volume shifts in North America from fourth quarter 2025 were expected. And we also had an early start to the North America season due to favorable weather." That matters for the Q2 print because some of what looked like Q1 upside was really Q4-2025 business landing a quarter early — meaning Q2 comparisons need to be read in the context of the full first half rather than in isolation. Management explicitly said as much on the call: "it's more meaningful to look at our business by half... performance in Northern and Southern Hemisphere is more complete when looking at the 6-month period."
Notably, CFO David Johnson acknowledged that the first half of 2026 is now tracking above the roughly 7% underlying growth pace originally built into guidance, telling analysts that "we do expect the first half to be a little bit stronger than that" 7%-ish figure — which sets an elevated bar for the Q2 segment/organic growth print.
1. Seed segment — pricing power and the corn/soybean mix shift. In Q1, Seed price/mix rose 3% globally with gains in every region, while volume was up 6% on the North American timing shift. For 2026 overall, farmers are expected to shift roughly 3-4% of planted corn area to soybeans in the U.S., with Enlist E3 soybeans now approaching the #1 branded position at roughly 65% of U.S. soybean acres. Watch for commentary on how this acreage mix (lower-value soybeans vs. higher-value corn) nets out against continued price-for-value execution and out-licensing income (the Bayer trait agreement) as Corteva approaches "royalty positive" status later this year.
2. Crop Protection — Latin America volume trajectory. Management's full-year view calls for the CP industry to see its first return to (modest) growth in several years, with Corteva expecting mid-single-digit volume gains outpacing low-single-digit pricing declines. Second-half volume growth is expected to accelerate meaningfully, led by Latin America new products, spinosyns, and a biologicals portfolio that skews to the back half of the year — but Q2 begins to show early signs of that Southern Hemisphere season ramp (safrinha corn planting, biological product demand tied to fertilizer substitution).
3. Guidance: reaffirm, raise, or trim? Full-year 2026 guidance, first issued in February and reaffirmed at Q1, calls for Operating EBITDA of $4.0-4.2 billion (22-23% margin) and Operating EPS of $3.45-3.70, roughly 7% growth at the midpoint versus 2025's actual $3.848 billion EBITDA and $3.34 operating EPS. Given the stronger-than-expected first half, investors will be watching whether management raises guidance outright (as it did a year ago after a strong 1H 2025) or simply reaffirms while flagging offsetting headwinds — management indicated on the Q1 call that "the year is shaping up to be a little better than we expected in February," while also citing $40 million of oil-price-related cost headwinds baked into guidance.
4. Escalating Middle East conflict and oil prices — has the risk grown? Back in May, Corteva said its own commercial exposure to Middle East conflict was minimal, with the primary channel being higher oil prices, and that the year's roughly $40 million headwind was "manageable within our current guidance range." Since then, the geopolitical backdrop has intensified: as of July 29, 2026, reports indicate the U.S. military intercepted Iranian ballistic missiles and conducted strikes alongside Saudi Arabia against Iran-backed groups in Iraq, with oil prices jumping and tanker traffic through the Strait of Hormuz reportedly halted. This is a materially different situation than the one management sized in May, and investors should listen closely for whether the energy-cost assumption embedded in guidance still holds, and whether it changes farmer economics (fertilizer/fuel costs) in Latin America, where management already said it is "watching" the impact on safrinha corn and soybean planting decisions.
5. Bad debt / working capital in Latin America. SG&A grew roughly $100 million in Q1, about a quarter of which was bad debt; management said past-due balances as a percentage of sales remained in line with (or slightly better than) last year, but this is a line item to track again as Brazilian input costs (fertilizer, energy) rise.
6. China supply/demand for crop chemicals. Management flagged early, tentative signs that Chinese active-ingredient exports into Brazil are slowing and that China's export controls/VAT changes are pushing certain AI prices up roughly 8% — a potential positive read for global crop-protection pricing, though management cautioned the 2026 impact is likely minimal given Brazilian inventory levels already in place, with any benefit more likely visible in late 2026/2027.
The dominant strategic storyline for CTVA right now is the planned separation, still targeted for the fourth quarter of 2026. Several milestones have occurred since the Q1 call:
Given the timeline, Q2 commentary on separation costs, headquarters decisions, capital structure finalization, and any changes to the Q4 2026 target date will likely matter as much to the stock as the quarterly numbers themselves.
Corteva entered 2026 planning to complete approximately $500 million of share repurchases in the first half of the year as part of returning significant capital to shareholders. Free cash flow in Q1 was distorted by the cash payment tied to the Bayer litigation settlement and separation-related items; management reiterated that, excluding those discrete items, full-year free cash flow conversion should be in line with the mid-term target set out at the 2024 Investor Day (roughly 40-50%, with a 45% midpoint).
Agribusiness peer Bunge (BG) reported strong Q2 results on July 29, 2026, raising its full-year adjusted EPS outlook to $9.25-$9.75 after soybean and softseed sales jumped nearly 90%, with adjusted per-share earnings of $2.00 topping the $1.97 analysts expected. While Bunge is a processor rather than an input supplier, robust downstream oilseed demand is a supportive signal for Corteva's Seed segment, particularly its soybean/Enlist technology penetration heading into the back half of the year.
Corteva goes into this print from a position of operating strength — Q1 beat expectations, full-year guidance was reaffirmed and, in management's words, "de-risked" slightly for the second half, and the company is executing on cost, royalty, and productivity self-help levers. The stock's run to 52-week highs into the print reflects confidence in both the fundamental algorithm and the value-unlock potential of the Vylor/Corteva separation. The bigger swing factors for Q2 are less about the underlying seed/crop-protection demand backdrop (which looks solid) and more about (1) how much of the "beat" is really H1 timing versus durable full-year strength, (2) whether the escalating Middle East conflict introduces a bigger oil/input-cost drag than the $40 million currently assumed, and (3) fresh detail on separation costs, capital structure, and timeline ahead of the September 15 Investor Day.